Keros Therapeutics, INC 8-K filings

Keros Therapeutics' Chair and CEO, Jasbir Seehra, will participate in fireside chat presentations at the TD Cowen and Leerink Partners healthcare conferences in March 2025.

Keros Therapeutics announces its Q4 and full year 2024 financial results, highlighting a strengthened cash position due to a $200 million upfront payment from Takeda and progress in its clinical trials.

Keros Therapeutics' CEO, Jasbir Seehra, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025.

Keros Therapeutics' global license agreement with Takeda for elritercept has become effective, resulting in a $200 million upfront payment to Keros.

Keros Therapeutics has voluntarily halted all dosing in its Phase 2 TROPOS trial for cibotercept due to new observations of pericardial effusion adverse events.

Keros Therapeutics provides a corporate update, including a halt to higher dose arms in a Pulmonary Arterial Hypertension trial, progress on other clinical programs, and a significant licensing agreement with Takeda for elritercept.

Keros Therapeutics has voluntarily paused dosing in the 3.0 mg/kg and 4.5 mg/kg arms of its Phase 2 TROPOS trial for pulmonary arterial hypertension due to unexpected safety issues.

Keros Therapeutics presented promising data from its Phase 2 trials of elritercept, showing durable transfusion independence in MDS patients and improvements in hematopoiesis and symptoms in myelofibrosis patients.

Keros Therapeutics has granted Takeda exclusive global rights to develop and commercialize elritercept, a promising drug for blood disorders, in a deal that could exceed $1.1 billion.

Keros Therapeutics' CEO, Jasbir Seehra, will participate in fireside chat presentations at two healthcare conferences in early December.

Keros Therapeutics reported completing enrollment in a Phase 2 trial ahead of schedule and provided a financial update for the third quarter of 2024.

Keros Therapeutics CEO, Jasbir Seehra, will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 13, 2024.

Keros Therapeutics has appointed Yung H. Chyung, M.D., as its new Chief Medical Officer, effective November 1, 2024.

Keros Therapeutics has completed enrollment of 113 patients in its Phase 2 TROPOS trial for pulmonary arterial hypertension, exceeding the initial target of 90 patients, with topline data expected in the second quarter of 2025.

Keros Therapeutics has completed screening for its Phase 2 TROPOS trial of cibotercept in pulmonary arterial hypertension, with topline data anticipated in the second quarter of 2025.

Keros Therapeutics' CEO, Jasbir Seehra, will participate in fireside chat presentations at three healthcare conferences in September 2024.

Keros Therapeutics provides an update on its clinical programs for elritercept, cibotercept, and KER-065, along with key milestones.

Keros Therapeutics announced its second quarter 2024 financial results, highlighting increased research and development expenses and continued progress in its clinical programs.

Keros Therapeutics has filed a prospectus supplement for a potential at-the-market offering of up to $350 million of its common stock.

Keros Therapeutics has announced a series of leadership changes, including the appointment of Jasbir Seehra as Chair of the Board and the promotion of Christopher Rovaldi to President, effective July 1, 2024.

Keros Therapeutics announced encouraging new data from Phase 2 trials of elritercept (KER-050) in myelodysplastic syndromes (MDS) and myelofibrosis (MF), showing durable transfusion independence and clinical benefits.

Keros Therapeutics received positive feedback from the FDA regarding its KER-050 program and expects to complete enrollment for its KER-012 Phase 2 trial by the end of 2024.

Keros Therapeutics' CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024.

Keros Therapeutics held its 2024 Annual Meeting of Stockholders, electing three directors, ratifying its accounting firm, and approving executive compensation on an advisory basis.

Keros Therapeutics has appointed Jean-Jacques Bienaim, a seasoned biotech executive, to its Board of Directors, effective June 1, 2024.

Keros Therapeutics announced its first quarter 2024 financial results, highlighting increased research and development expenses and a net loss, while also providing updates on its clinical programs.

Keros Therapeutics has been granted Fast Track designation by the FDA for its drug KER-050, aimed at treating anemia in adult patients with lower-risk myelodysplastic syndromes.

Keros Therapeutics provides an update on its clinical programs for KER-050, KER-012, and KER-065, highlighting positive results and future milestones.

Keros Therapeutics' CEO, Jasbir Seehra, will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12, 2024.

Keros Therapeutics announces the resignation of its Chief Medical Officer, Simon Cooper, effective March 12, 2024, as the company initiates a search for his replacement.